Etomidate

Etomidate Basic information
Product Name:Etomidate
Synonyms:(r)-(+)-1-(alpha-methylbenzyl)imidazole-5-carboxylicacidethylester;1-(1-phenylethyl)-,ethylester,(r)-1h-imidazole-5-carboxylicaci;1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester;1-(1-phenylethyl)-1h-imidazole-5-carboxylicacidethylester;Amidate, R16659;Imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, ethyl ester, (R)-(+);1-[(R)-α-Methylbenzyl]-1H-imidazole-5-carboxylic acid ethyl ester;Etomidate (200 mg)
CAS:33125-97-2
MF:C14H16N2O2
MW:244.29
EINECS:251-385-9
Product Categories:EVISTA;Other APIs;Heterocycles;Intermediates & Fine Chemicals;GABA/Glycine receptor;GABA;chiral;Aromatics Compounds;Aromatics;Pharmaceuticals;Intermediate;API;pharmaceutical;33125-97-2
Mol File:33125-97-2.mol
Etomidate Structure
Etomidate Chemical Properties
Melting point 72-74°C
alpha D20 +66° (c = 1 in ethanol)
Boiling point 160-162 °C(Press: 1 Torr)
density 1.11±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: >10 mg/mL
form powder
pkapKa 4.24(H2O t=25.0) (Uncertain)
color white
Merck 14,3881
CAS DataBase Reference33125-97-2(CAS DataBase Reference)
NIST Chemistry ReferenceEtomidate(33125-97-2)
Safety Information
Hazard Codes Xn
Risk Statements 22
Safety Statements 36
RIDADR UN 3077 9 / PGIII
WGK Germany 3
RTECS NI4021500
HazardClass 9
PackingGroup III
HS Code 29332900
ToxicityLD50 in mice, rats (mg/kg): 29.5, 14.8-24.3 i.v. (Janssen)
MSDS Information
ProviderLanguage
Etomidate English
SigmaAldrich English
Etomidate Usage And Synthesis
Chemical PropertiesEtomidate is a white crystalline powder. easily soluble in water, methanol, ethanol and propylene glycol, soluble in chloroform, insoluble in acetone, insoluble in ether. Its effects on the central nervous system is similar to barbiturates.
OriginatorHypnomidate,Janssen,W. Germany,1977
UsesEtomidate is a GABAA receptors agonist with short-acting sedative, hypnotic, and general anesthetic properties. It is a unique drug used for induction of general anesthesia and sedation. It is also a hypnotic. Hypnotic effect of Etomidate is strong , and its efficacy is about 12 times higher than thiopental, it has no analgesic effect.
DefinitionChEBI: Etomidate is the ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity. It has a role as an intravenous anaesthetic and a sedative. It is a member of imidazoles and an ethyl ester. It derives from a 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid.
Brand nameAmidate (Hospira);Hypnomidate concentrate;Hypnomidate injection;Hypromidate;Nalgol;Sibu.
Therapeutic FunctionHypnotic
World Health Organization (WHO)Etomidate, a potent hypnotic agent, was introduced in 1977 for use as an intravenous anaesthetic. Its prolonged use can inhibit adrenal steroidogenesis and, following reports of reduced serum cortisol levels unresponsive to ACTH injection, the manufacturer suspended promotion of etomidate for sedation in intensive care in 1983. In 1985 regulatory action taken only in the United Kingdom further restricted use of the drug to induction of anaesthesia. Etomidate remains widely available and is currently registered for induction of anaesthesia in 34 countries and for maintenance of anaesthesia in 17 countries. It has never been registered for sedation.
Biological FunctionsThe pharmacological properties of etomidate (Amidate) are similar to those of the barbiturates, although its use may provide a greater margin of safety because of its limited effects on the cardiovascular and respiratory systems. Since it has a relatively short elimination halflife (t1/2β = 2.9 hours), in addition to its use as an induction agent, etomidate has been used as a supplement to maintain anesthesia in some critically ill patients. Etomidate is rapidly hydrolyzed in the liver.
General DescriptionEtomidate is a carboxylated imidazole intended for the inductionof general anesthesia. It is marketed as the morepotent R (+) isomer. It is believed to exert its anestheticeffect via positive modulation of the GABAA receptor. Itis not water soluble and is available in the United States as a2-mg/mL solution containing 35% v/v propylene glycol andin Europe as a soybean oil and medium-chain triglyceridesformulation. The propylene glycol has been associatedwith moderate-to-severe pain on injection and irritation ofthe vascular tissue. A high incidence of skeletal musclemovements were noted in about 32% of patients followingetomidate injection. Case reports of seizures are also foundin the literature.
Biological ActivityEtomidate is a general anesthetic with GABA modulatory and GABA-mimetic actions; selectively interacts with β 2- and β 3-subunit containing GABAA receptors. Short acting and potent hypnotic, with low toxicity.The possible neuroprotective effect of etomidate against streptozotocin-induced (STZ-induced) hyperglycaemia were investigated in the rat brain and spinal cord. Etomidate treatment demonstrated neuroprotective effect on the neuronal tissue against the diabetic oxidative damage.
Clinical UseEtomidate should only beused for induction of anesthesia when the cardiac benefitsoutweigh the risks associated with adrenal insufficiency.Etomidate is quickly distributed throughout most organsin the body after intravenous administration and the tissueconcentrations equal and sometimes exceed the plasmaconcentrations. The lipid solubility of the drug allows it torapidly penetrate into the brain with peak concentrationsoccurring within 1 minute of administration. Etomidate israpidly metabolized in the plasma and liver via esterases.About 75% of the drug is eliminated in the urine as the inactiveester hydrolyzed carboxylic acid.
Side effectsEtomidate may cause pain on injection and may produce myoclonic muscle movements in approximately 40% of patients during its use as an induction anesthetic. In addition, etomidate can suppress the adrenocortical response to stress, an effect that may last up to 10 hours.
Veterinary Drugs and TreatmentsEtomidate may be useful as an alternative to thiopental or propofol for anesthetic induction in small animals, particularly in patients with preexisting cardiac dysfunction, head trauma, or that are critically ill.
Drug interactionsPotentially hazardous interactions with other drugs
Adrenergic neurone blockers: enhanced hypotensive effect.
Antihypertensives: enhanced hypotensive effect.
Antidepressants: avoid MAOIs for 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics.
Antipsychotics: enhanced hypotensive effect.
MetabolismEtomidate is hydrolyzed by hepatic esterases to the corresponding inactive carboxylic acid, with subsequent renal and biliary excretion terminating its action. Its apparent elimination half-life is approximately 5 to 6 hours, with a volume of distribution of 5 to 7 L/kg. Changes in hepatic blood flow or hepatic metabolism will have only moderate effects on etomidate disposition. Concerns regarding the ability of etomidate to precipitate myoclonic jerks and inhibit adrenal steroid synthesis have been reported.
storageRoom temperature
Mode of actionThe exact mechanism of action of etomidate is unknown. It is felt to induce sedation by interaction with GABA receptors. and likely enhances the activity of a-aminobutyric acid. However, it is not structurally related to benzodiazepines or to barbiturates. Of significantnote, etomidate exhibits no analgesic properties.
metomidate Benzocaine Ethanol Ethyl formate Benzyl salicylate Urethane Ethylparaben Carbobenzoxyhydrazide Ethyl chloroformate ISOXADIFEN-ETHYL Imidazole Ethyl acetate CARBOXYLIC ACID Benzyl chloroformate Benzyl acetate Methyl acrylate Benzyl benzoate Benzyl nicotinate

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.